Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bacterial Meningitis I: Introduction

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...

Bacterial Meningitis II: Pathophysiology

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...

Viral Meningitis

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...

Vaccinations

Vaccinations

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Diphtheria

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The COVID-19 pandemic and acute rheumatic fever inequities, Aotearoa New Zealand, 2020-2022.

The New Zealand medical journal·2026

Same author

Evaluating Indigenous health workforce development interventions for Māori and Indigenous Pacific tertiary students: success at Waipapa Taumata Rau | The University of Auckland (2016-2023).

The New Zealand medical journal·2025

Same author

Correction: High seroprevalence of antibodies against SARS-CoV-2 among healthcare workers 8 months after the first wave in Aden, Yemen.

PLOS global public health·2024

Same author

High seroprevalence of antibodies against SARS-CoV-2 among healthcare workers 8 months after the first wave in Aden, Yemen.

PLOS global public health·2023

Same author

Seroprevalence of anti-SARS-CoV-2 antibodies among blood donors from December 2020 to June 2021 in Koutiala district, Mali.

PLOS global public health·2023

Same author

Shifting to Tele-Mental Health in humanitarian and crisis settings: an evaluation of Médecins Sans Frontières experience during the COVID-19 pandemic.

Conflict and health·2022

Search research articles

Related Experiment Video

Updated: May 10, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

The Northland emergency meningococcal C vaccination programme.

Clair Mills¹, Liane Penney

¹Northland District Health Board, Private Bag 9742, Whangarei 0148, New Zealand. clair.mills@northlanddhb.org.nz

The New Zealand Medical Journal

|June 26, 2013

Summary

An emergency meningococcal C vaccination program in New Zealand achieved 73% coverage, demonstrating that high vaccination rates are possible. Outreach services were crucial for reaching diverse populations and reducing barriers.

More Related Videos

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Related Experiment Videos

Last Updated: May 10, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Area of Science:

Public Health
Epidemiology
Vaccinology

Background:

Meningococcal group C outbreaks pose a significant public health risk.
Emergency vaccination programs are critical for controlling infectious disease outbreaks.

Purpose of the Study:

To describe an emergency meningococcal C vaccination program in Northland, New Zealand.
To achieve 85% vaccination coverage in children and youth aged 12 months to <20 years.

Main Methods:

Targeted an estimated population of 44,000 children and youth.
Utilized a multi-pronged delivery strategy including schools, general practices, community clinics, and home-based services.
Employed a meningococcal serogroup C conjugate vaccine.

Main Results:

Vaccinated 32,410 individuals, achieving 73% overall coverage (72% Maori, 75% non-Maori).
Coverage varied by age, ethnicity, school decile, and location.
Highest coverage in 5 to <13 years (84% Maori, 81% non-Maori); lowest in 17 to <20 years (46% Maori, 63% non-Maori).

Conclusions:

Equitable, high vaccination coverage is achievable during emergency programs in New Zealand.
Diverse service delivery options, including outreach, are essential to overcome access barriers.
The program provided valuable insights into adapting services for diverse population needs.